Amendment 1 Ryszard Czarnecki, Cristian Terheş on behalf of the ECR Group

Report A9-0133/2024

Petri Sarvamaa

Discharge 2022: European Medicines Agency 2023/2156(DEC)

Motion for a resolution Paragraph 2 a (new)

Motion for a resolution

Amendment

2 a. Notes with concern that in 2021 and 2022 around 86 % of EMA's budget was funded by private pharmaceutical firms; highlights that such a percentage can appear incompatible with independent decision making, and that the EMA's action cannot be qualified as driven by public interest only^{1a};

Or. en

AM\P9_AMA(2024)0133(001-004)EN.docx

PE760.610v01-00

^{1a} https://www.ema.europa.eu/en/aboutus/how-we-work/governancereporting/funding

Amendment 2 Ryszard Czarnecki, Cristian Terheş on behalf of the ECR Group

Report A9-0133/2024

Petri Sarvamaa

Discharge 2022: European Medicines Agency 2023/2156(DEC)

Motion for a resolution Paragraph 5 a (new)

Motion for a resolution

Amendment

5 a. Notes with concern that in 2022 two new COVID-19 vaccines were approved for use throughout the Union and in total seven COVID-19 vaccines were authorised;

Or. en

Amendment 3 Ryszard Czarnecki, Cristian Terheş on behalf of the ECR Group

Report A9-0133/2024

Petri Sarvamaa

Discharge 2022: European Medicines Agency 2023/2156(DEC)

Motion for a resolution Paragraph 7 a (new)

Motion for a resolution

Amendment

7 a. Notes with concern that during the COVID pandemic, all the vaccines available in the Member States were in phase 3 clinical trials (phase of experimentation on humans);

Or. en

Amendment 4 Ryszard Czarnecki, Cristian Terheş on behalf of the ECR Group

Report A9-0133/2024

Petri Sarvamaa

Discharge 2022: European Medicines Agency 2023/2156(DEC)

Motion for a resolution Paragraph 7 b (new)

Motion for a resolution

Amendment

7 b. Regrets that EMA's assessment of the side effects of the COVID-19 vaccines lacked transparency and was overdue and overly lenient with regard to the decisions taken or alerts issued by the national authorities;

Or. en